National Biotechnology Research Park

Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah

Retrieved on: 
Wednesday, September 21, 2022

Parties agree to collaborate on research in genetics, regenerative and alternative medicine

Key Points: 
  • Parties agree to collaborate on research in genetics, regenerative and alternative medicine
    PETALING JAYA, Malaysia, Sept 21, 2022 - (ACN Newswire) - Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.
  • Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min, said, "We are happy to assist UMS undergraduates in pursuing their R&D goals so that they have a better understanding of their field of study.
  • The signing of the LOI followed UMS' visit to MGRC's Biosafety Level 2 cGMP (Current Good Manufacturing Practice)-certified laboratory, which is used for the production of cell therapies, including CAR T-cell therapies for various cancers.
  • Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

EpiBone CEO and Co-Founder Dr. Nina Tandon Selected to Participate in White House Summit

Retrieved on: 
Wednesday, September 21, 2022

NEW YORK, Sept. 21, 2022 /PRNewswire-PRWeb/ -- EpiBone CEO and Co-Founder Dr. Nina Tandon participated as a speaker at the White House Summit on Biotechnology & Biomanufacturing for the American Bioeconomy on September 14, 2022. The summit brought together government and private sector leaders as a first step in launching the Biden Administration's National Biotechnology and Biomanufacturing Initiative, a whole-government approach to advancing biotechnology and biomanufacturing to create innovation in health, climate change, energy, food security, agriculture, supply chain resilience, and national and economic security.

Key Points: 
  • NEW YORK, Sept. 21, 2022 /PRNewswire-PRWeb/ -- EpiBone CEO and Co-Founder Dr. Nina Tandon participated as a speaker at the White House Summit on Biotechnology & Biomanufacturing for the American Bioeconomy on September 14, 2022.
  • As CEO and co-founder of EpiBone, Inc., Tandon bridges the realms of business and science, with decades of experience in tissue engineering and bioreactor design.
  • In her work at EpiBone, Tandon leads the company in its mission to use groundbreaking research to transform skeletal repair.
  • To learn more about Dr. Nina Tandon and the work of the EpiBone team, visit https://www.epibone.com/.

Geno CEO Applauds Greater Government Investment at White House Summit on Biomanufacturing

Retrieved on: 
Wednesday, September 14, 2022

WASHINGTON, Sept. 14, 2022 /PRNewswire/ -- Today, Genomatica (Geno) CEO Christophe Schilling applauded recent government investment to promote the growth of domestic biomanufacturing amid the newest White House Executive Order on emerging biotechnologies. Speaking at the White House Summit on Biotechnology and Biomanufacturing for the American Bioeconomy, Schilling reiterated that the Order will be an important driver of more resilient domestic supply chains through domestic infrastructure, delivering sustainable materials at scale, and a key component of the Biden Administration's climate resilience plan.

Key Points: 
  • WASHINGTON, Sept. 14, 2022 /PRNewswire/ -- Today, Genomatica (Geno) CEO Christophe Schilling applauded recent government investment to promote the growth of domestic biomanufacturing amid the newest White House Executive Order on emerging biotechnologies.
  • "It's not often that one action fuels the economy, combats climate change and strengthens supply chains at the same time,"said Geno CEO Christophe Schilling.
  • Today's Summit and Executive Order jumpstarts this process, and Geno looks forward to continued engagement with the White House to put our unique solutions to work."
  • Geno already stands at the forefront of powering technologies that enable large scale biomanufacturing of sustainable materials.

LanzaTech CEO Highlights Company Role as a Synthetic Biology Leader at White House Event Celebrating Biotechnology

Retrieved on: 
Wednesday, September 14, 2022

Dr. Holmgren met with Director of the National Economic Council Brian Deese, Acting Director of the White House Office of Science and Technology Policy.

Key Points: 
  • Dr. Holmgren met with Director of the National Economic Council Brian Deese, Acting Director of the White House Office of Science and Technology Policy.
  • LanzaTech is leading by example and Dr. Holmgren told the gathered crowd that she has set a grand challenge for her company.
  • This press release includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of LanzaTech.
  • All forward-looking statements attributable to LanzaTech or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements.

Danimer Scientific CEO Stephen Croskrey to Take Part in White House-Hosted Summit on Biotechnology and Biomanufacturing

Retrieved on: 
Wednesday, September 14, 2022

Danimer Scientific, Inc. (NYSE: DNMR) (Danimer or the Company) chief executive officer Stephen Croskrey will be taking part in a high-level Summit on Biotechnology & Biomanufacturing for the American Bioeconomy, being hosted today by the White House Administration.

Key Points: 
  • Danimer Scientific, Inc. (NYSE: DNMR) (Danimer or the Company) chief executive officer Stephen Croskrey will be taking part in a high-level Summit on Biotechnology & Biomanufacturing for the American Bioeconomy, being hosted today by the White House Administration.
  • At the summit, Croskrey will take part in a panel on biomanufacturing for the bioeconomy.
  • Im honored to be included in this summit on behalf of Danimer Scientific and the bioplastics industry, Croskrey said.
  • Since our companys founding in 2004, Danimer has been laser-focused on finding environmentally friendly, economically feasible solutions to the ever-growing plastic waste crisis.

GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference

Retrieved on: 
Wednesday, March 16, 2022

CSO Mark Newman, PhD to Participate in Fireside Chatwith Maxim Analyst Jason McCarthy, PhD

Key Points: 
  • CSO Mark Newman, PhD to Participate in Fireside Chatwith Maxim Analyst Jason McCarthy, PhD
    ATLANTA, GA , March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc .
  • (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers,has been invited to present at Maxim Groups2nd annual Virtual Growth Conference to be held March 28-30, 2022.
  • GeoVaxs Chief Scientific Officer, Mark Newman PhD, will also participate in a live fireside chat with Maxims Head of Biotechnology Research, Jason McCarthy, PhD, on March 30, 2022, discussing developments in cancer vaccines and immuno-oncology.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms.

Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer

Retrieved on: 
Monday, November 22, 2021

MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today the appointment of Ian Somaiya as Chief Financial Officer and Chief Business Officer.

Key Points: 
  • MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today the appointment of Ian Somaiya as Chief Financial Officer and Chief Business Officer.
  • Mr. Somaiya brings to Elucida more than 20 years of experience in finance and healthcare as a highly regarded biotechnology research analyst as well as operational experience as Chief Financial Officer of TCR2 Therapeutics.
  • Most recently, he was Chief Financial Officer of TCR2 Therapeutics where he successfully navigated the company through its IPO and two follow-on financings.
  • Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle CDot drug delivery platform.